Fresenius Medical Care
FMS
233 hedge funds and large institutions have $781M invested in Fresenius Medical Care in 2018 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 78 increasing their positions, 56 reducing their positions, and 19 closing their positions.
84% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 19
39% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 56
6% more funds holding
Funds holding: 220 → 233 (+13)
0% more capital invested
Capital invested by funds: $779M → $781M (+$2.04M)
0.15% more ownership
Funds ownership: 4.81% → 4.96% (+0.15%)
Top Buyers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$16M |
| 2 |
HL
Harding Loevner
Bridgewater,
New Jersey
|
+$12.8M |
| 3 |
Morgan Stanley
New York
|
+$9.87M |
| 4 |
TIM
Thornburg Investment Management
Santa Fe,
New Mexico
|
+$6.42M |
| 5 |
Millennium Management
New York
|
+$3.5M |
Top Sellers
FMS Hedge Fund Activity: Q1 2018 in Review
233 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Fresenius Medical Care (FMS) for Q1 2018, worth a combined $781M — up 0.26% from $779M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new FMS positions and 19 closed out — a net gain of 16 holders — while 78 added to existing stakes and 56 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $16M. The largest seller was Marathon Asset Management (UK), cutting an estimated $20.2M.
- 233 institutional investors held Fresenius Medical Care (FMS) as of Q1 2018, up from 220 in Q4 2017.
- Funds reported $781M of Fresenius Medical Care stock for Q1 2018, up 0.26% quarter-over-quarter.
- 35 funds opened new Fresenius Medical Care positions in Q1 2018 and 19 closed out, a net change of +16 holders.
- The largest Fresenius Medical Care buyer in Q1 2018 was Arrowstreet Capital, an estimated $16M added.
- The largest Fresenius Medical Care seller in Q1 2018 was Marathon Asset Management (UK), an estimated $20.2M sold.
Based on aggregated 13F filings for Q1 2018.